Accessibility Menu

Clinuvel Pharmaceuticals(NASDAQ) CUVL

Market Cap$339.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
$6.90
+2.60%
+0.17Today

Clinuvel Pharmaceuticals Financials at a Glance

Market Cap

$339.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.41

P/E Ratio

16.15

Dividend

$0.03

Beta (Volatility)

0.68 (Low)

Price

$6.90

Volume

1,644

Open

$6.71

Previous Close

$6.90

Daily Range

$6.71 - $6.90

52-Week Range

$5.98 - $9.00

Estimated Earnings Date

Sep 1, 2026

CUVL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited is a biopharmaceutical firm focused on developing and marketing therapies for individuals with genetic, metabolic, and severe medical conditions. The company operates in Australia, Europe, the United States, and Switzerland, with its flagship product, SCENESSE, designed to protect patients suffering from erythropoietic protoporphyria (EPP) from light-induced damage.

Products and Services
  • SCENESSE: A systemic photoprotective medication for EPP patients
  • CUV9900: An alpha-melanocyte stimulating hormone analogue
  • Parvysmelanotide (VLRX001): Stimulates extended cellular activity
Growth Outlook
  • Partnership with HK Winhealth Pharma to expand SCENESSE in China
  • Strong pipeline with innovative therapies targeting unmet medical needs
  • Increasing global awareness of EPP and related conditions driving demand
Financial Highlights
  • Recent quarterly revenue of 36.25 million AUD, reflecting strong market performance
  • Net income of 10.25 million AUD for the latest quarter, showcasing profitability
  • Cash and short-term investments totaling 232.77 million AUD, indicating solid liquidity
Clinuvel Pharmaceuticals Limited is well-positioned in the biotechnology sector, focusing on innovative solutions for rare medical conditions. The company's commitment to research and development is evident in its diverse product pipeline, which aims to address significant unmet medical needs. The recent partnership in China highlights the potential for market expansion, while the financial metrics indicate a robust operational foundation. With a strong cash position and a focus on growth, Clinuvel Pharmaceuticals presents an intriguing opportunity for investors interested in the biotechnology landscape.
AI Generated • Aug 4, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Lachlan Hay

Website

www.clinuvel.com

Headquarters

Melbourne, VIC 3000, AU

CUVL Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

13.88%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

6.19%

Dividend Yield

0.49%

Payout Ratio

N/A

Stock Overview

Market Cap

$339.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.41M

Volume

1.64K

Avg. Volume

3.56K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Clinuvel Pharmaceuticals Performance Analysis

Clinuvel Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 47,667,442N/A
20232023-06-30USD 52,687,10410.5%
20242024-06-30USD 57,789,8619.7%
20252025-06-30USD 61,536,3236.5%
Clinuvel Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD 0.29N/A
20232023-06-30USD 0.4035.8%
20242024-06-30USD 0.4615.2%
20252025-06-30USD 0.471.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$339.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,781.56-0.00%
^DJIDJI
$53,774.55-0.00%
^IXICNASDAQ
$26,681.72-0.00%
BTCBitcoin
$62,986.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About CUVL

What is the current price of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals is trading at $6.90 per share.

What is the 52-week range for Clinuvel Pharmaceuticals?

Over the past 52 weeks, Clinuvel Pharmaceuticals has traded between $5.98 and $9.00.

How much debt does Clinuvel Pharmaceuticals have?

As of the most recent reporting period, Clinuvel Pharmaceuticals reported total debt of $346.37K.

How much cash does Clinuvel Pharmaceuticals have on hand?

Clinuvel Pharmaceuticals reported $18.36M in cash and cash equivalents in its most recent financial results.

What is Clinuvel Pharmaceuticals’s dividend yield?

Clinuvel Pharmaceuticals currently has a dividend yield of 0.49%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services